$10 Billion Deal, page-173

The Biotron Limited (ASX: BIT) share price has rocketed 40% higher to 14 cents after the drug development company announced that its BIT225-009 HIV-1 Phase 2 data would be presented at an upcoming meeting in the United States. Biotron’s shares have been on fire since it released results which indicated that BIT225 is having a unique effect in patients, over and above viral suppression seen with current antiretroviral drugs. It will now present this data at the HIV DART and Emerging Viruses 2018 meeting in Florida at the end of the month after being accepted by organisers. Management advised that the biannual meeting aims to bridge the gap between the latest scientific developments and routine clinical practice in the context of HIV infection and emerging viruses.